Unobtrusive Sensing of Medication Intake ("USE-MI") — USE-MI  

Medication Adherence Clinical Trial

Official title: Unobtrusive Sensing of Medication Intake ("USE-MI")

Status Recruiting

Clinical Trial Summary

The purpose of this study is to test the USE-MI system hardware and software to see if it can accurately measure when subjects take their HIV-related medications and help them remember to take these medications. With the use of a smartwatch and smartphone "app", investigators hope to be able to monitor medication adherence in real-time and send subjects electronic reminders when they may have forgotten to take their medication.

Clinical Trial Description

Human immunodeficiency virus (HIV) treatment is most likely to be successful when patients are committed to taking their medications as prescribed (medication adherence). For maximum benefit, researchers found that patients receiving antiretroviral therapy (ART) to treat HIV infection and pre-exposure prophylaxis (PrEP) to prevent HIV infection have need consistent, high levels of adherence for maximum benefit. However, some patients struggle to take their HIV-related medications regularly and that can lead to losing on the benefits the medication can provide - either suppressing the HIV infection so people do not get sick from it or transmit it, or failing to prevent infection when someone is exposed.

Objectives: Conduct an evaluation of USE-MI to assess accuracy, robustness, acceptability of the system.

All subjects will continue to take their ART or PrEP medication as prescribed by their regular doctor. The USE-MI system is being developed as a behavioral intervention to enhance medication adherence. In the pilot phase, the investigators plan to enroll 10 subjects to use the USE-MI system for 1 month to get initial feedback about the system. In the second phase, up to 50 subjects will begin using the USE-MI for up to 6 months to assess accuracy, robustness and acceptability of the system. ;

Related Conditions & MeSH terms

• Medication Adherence

• NCT number: NCT03571022
• Study type: Interventional
• Source: Swedish Medical Center
• Contact: Jacob Karr
• Phone: 206-215-4226
• Email: jacob.karr@swedish.org
• Status: Recruiting
• Phase: N/A
• Start date: January 8, 2019
• Completion date: December 31, 2025